The National MS
Society’s National Medical Advisory Committee recommends the following:
Society’s National Medical Advisory Committee recommends the following:
1) People with MS should
follow CDC guidelines and
these additional recommendations for people at risk for serious illnesses from COVID-19.
follow CDC guidelines and
these additional recommendations for people at risk for serious illnesses from COVID-19.
2)
People
with MS should continue disease modifying therapies (DMTs) and discuss specific
risks with their MS healthcare provider prior to stopping a DMT.
People
with MS should continue disease modifying therapies (DMTs) and discuss specific
risks with their MS healthcare provider prior to stopping a DMT.
3)
Before
starting a cell depleting DMT* or a DMT that carries warnings of potentially severe
increase in disability after stopping**, people with MS and their MS healthcare
providers should consider specific risks (e.g. age, comorbid health conditions,
location) and benefits.
Before
starting a cell depleting DMT* or a DMT that carries warnings of potentially severe
increase in disability after stopping**, people with MS and their MS healthcare
providers should consider specific risks (e.g. age, comorbid health conditions,
location) and benefits.
These recommendations
are the expert opinion of the National Medical Advisory Committee and are based
on their clinical experience and assessment of the limited data available
regarding COVID-19 and MS DMTs. They have been endorsed by the Consortium of
Multiple Sclerosis Centers (CMSC) and members of the MS Coalition***. We are
continuing to monitor this quickly evolving situation and these recommendations
may be modified as more data becomes available.
are the expert opinion of the National Medical Advisory Committee and are based
on their clinical experience and assessment of the limited data available
regarding COVID-19 and MS DMTs. They have been endorsed by the Consortium of
Multiple Sclerosis Centers (CMSC) and members of the MS Coalition***. We are
continuing to monitor this quickly evolving situation and these recommendations
may be modified as more data becomes available.
* Cell depleting
therapies include: Lemtrada, Mavenclad, Ocrevus and Rituxan (used off-label in
MS)
therapies include: Lemtrada, Mavenclad, Ocrevus and Rituxan (used off-label in
MS)
** DMTs with a
warning of potentially severe increase in disability after stopping include:
Gilenya and Tysabri
warning of potentially severe increase in disability after stopping include:
Gilenya and Tysabri
*** Members of the MS
Coalition include:
Coalition include:
Accelerated Cure Project for Multiple Sclerosis, Can Do MS,
Consortium of Multiple Sclerosis Centers, International Organization of Multiple
Sclerosis Nurses, MS Views and News,
Consortium of Multiple Sclerosis Centers, International Organization of Multiple
Sclerosis Nurses, MS Views and News,
Multiple Sclerosis Association of America, Multiple Sclerosis Foundation,
National Multiple Sclerosis Society and United Spinal Association
…………………………………………………………………………
This article is posted and shared by: #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews